Chronos Archive seal
The Human Record

Rabindranath Tagore

Case HR-ET021 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
7 May 1861 – 7 August 1941
Synthetic DOB
1946-05-07
Index visit
2026-02-17 at age 79
Synthetic MRN
HR-ET021-SYN

Teaching objective: Evaluation and management of lower urinary tract symptoms with urinary retention in a 79-year-old man, on the AUA benign prostatic hyperplasia guideline (2021, amended 2023), the AUA white paper on nonneurogenic chronic urinary retention, and the CMID benign prostatic hyperplasia monograph: the IPSS, post-void residual, urinalysis and culture, creatinine and kidney ultrasound for obstruction, PSA with shared decision-making about what it means at his age, an indwelling catheter with catheter-associated infection prevention and treatment (IDSA 2009), an alpha-blocker before a trial without catheter, a 5-alpha-reductase inhibitor for a large prostate, surgical options (laser enucleation, transurethral resection, and less invasive procedures such as prostatic artery embolization) weighed against frailty, a geriatric assessment (falls with alpha-blockers, delirium risk, cognition) with the AGS Beers Criteria 2023, a goals-of-care conversation, and his own values about surgery and his traditional remedies, recorded in his own terms and respected.

Historical timeline

DateEventClaims
7 May 1861Born in the Jorasanko mansion, Calcutta.CLM-0001
22 December 1901His school at Santiniketan begins formally.CLM-0003
1913Nobel Prize in Literature.CLM-0002, CLM-0004
Late 1937Loses consciousness; comatose and near death for a time.CLM-0005
15 September 1940Falls seriously ill at Kalimpong with lower abdominal pain and a severe urinary infection; brought back to Calcutta.CLM-0006
1940 to 1941Confined to the house by illness; seeks allopathic, homeopathic, and ayurvedic treatment.CLM-0007, CLM-0008, CLM-0016
30 July 1941Operation at Jorasanko.CLM-0009, CLM-0010, CLM-0011, CLM-0012, CLM-0014
7 August 1941Dies at Jorasanko, aged 80.CLM-0013, CLM-0015

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Rabindranath Tagore was born on 7 May 1861 in the Jorasanko mansion in Calcutta, the youngest son of Debendranath Tagore, a leader of the Brahmo Samaj; the name Tagore is the anglicised transliteration of Thakur. confirmed Rabindranath Tagore supports
Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports
D He was awarded the Nobel Prize in Literature in 1913 "because of his profoundly sensitive, fresh and beautiful verse, by which, with consummate skill, he has made his poetic thought, expressed in his own English words, a part of the literature of the West". confirmed The Nobel Prize in Literature 1913: Summary supports
Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports
D He started a school at Santiniketan that began formally on 22 December 1901 with five students, and around it he built Visva-Bharati, an unconventional university. confirmed History supports
Rabindranath Tagore supports
Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports
D He was known by the sobriquets Gurudeb, Kobiguru, and Bishwokobi. confirmed Rabindranath Tagore supports
Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports
D His last five years were marked by chronic pain and two long periods of illness: in late 1937 he lost consciousness and remained comatose and near death for a time, and in late 1940 a similar spell followed, from which he never recovered.
The 1937 illness is not further characterized in the sources read.
confirmed Rabindranath Tagore supports
D On 15 September 1940, while visiting Kalimpong, he fell seriously ill with severe pain in his lower abdomen; doctors diagnosed a severe urinary tract infection, and he was brought back, unconscious, to Calcutta.
The anchor for the synthetic urinary history.
probable Dinda A. India pays homage to Tagore on his 75th death anniversary supports
Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
D In the last two years of his life illness confined him to the house, with swollen feet, numbness of the fingers, and frequent fevers; women of his family and household nursed him at home. confirmed Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports
D He sought cure in allopathy, homeopathy, and ayurvedic medicine; physicians including Bidhan Chandra Roy and Nilratan Sarkar supervised his treatment; he is reported to have refused surgery despite repeated insistence from his doctors, to have sought a herbal cure, and to have said that he was more afraid of complicated medical treatment than of death.
The anchor for the documented preference in the synthetic episode; included with respect.
probable Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports
Dinda A. India pays homage to Tagore on his 75th death anniversary supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
D He was very anxious about the operation and asked several times whether it would hurt; a few days before it he asked for a prayer-poem asking not for rescue from danger but for courage in it. confirmed Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports
D He was operated on at Jorasanko, on a veranda outside his room made into an operating theatre, on 30 July 1941; one reference work instead says he dictated a poem on 30 July, a day before a scheduled operation.
The date is reported inconsistently.
probable Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports
Dinda A. India pays homage to Tagore on his 75th death anniversary supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
Rabindranath Tagore context
R Doctors reviewing his records for a 2016 exhibition said he had an enlarged prostate that was stopping his urine flow.
Retrospective medical reading of his final illness.
probable Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
R Accounts of the operation differ: one says the doctors could not operate on the enlarged prostate and instead performed a bypass to drain the accumulated urine and relieve pain; another says the operation was performed and was successful.
The nature of the operation is reported inconsistently.
disputed Dinda A. India pays homage to Tagore on his 75th death anniversary supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
R Present-day doctors believe that infection after the operation led to septicaemia and his death.
Retrospective interpretation.
possible Dinda A. India pays homage to Tagore on his 75th death anniversary supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
R A university vice-chancellor said in 2018 that he was suffering from cancer in his prostate; other accounts describe only an enlarged prostate.
Not adopted; the synthetic episode makes no cancer diagnosis and does not suggest one.
disputed Dinda A. India pays homage to Tagore on his 75th death anniversary supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore context
D He died on 7 August 1941, aged 80, at the Jorasanko house, after a prolonged period of suffering.
Record the death as a fact without detail.
confirmed Rabindranath Tagore supports
Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports
Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports
D He suffered the untimely deaths of his wife and three of his children; he took his daughter Renuka to hill stations in the Himalayas for her recovery from tuberculosis.
Family history only.
confirmed Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Benign prostatic hyperplasia with severe lower urinary tract symptoms (IPSS 26) and bladder outlet obstruction: prostate about 85 mL on ultrasound, smooth and benign on examination, PSA 4.9 ng/mL (PSA density 0.06) active confirmed both_with_link CLM-0006, CLM-0011
S Urinary retention with severe lower urinary tract symptoms (bladder scan 640 mL after voiding) and a raised creatinine, cause under evaluation resolved confirmed active CLM-0006, CLM-0011
S Chronic urinary retention from bladder outlet obstruction, low risk once drained (no hydronephrosis; creatinine normal after drainage), managed with an indwelling urethral catheter resolved confirmed active CLM-0006, CLM-0011
S Catheter-associated urinary tract infection with fever, without sepsis; resolved resolved confirmed active CLM-0006
S Mild frailty (Clinical Frailty Scale 5): slow gait (Timed Up and Go 15 seconds), needs help with heavy housework and travel; cognition normal (Mini-Cog 4) active confirmed active CLM-0007

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-02-17 Symptom score [AUASI] 26 http://loinc.org · 80891-5
S 2026-02-17 If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] 5 http://loinc.org · 81090-3
S 2026-02-17 US Urinary bladder Volume post void 640 mL (high)
Reference <=100 mL
http://loinc.org · 98856-8
S 2026-02-17 Leukocytes [#/area] in Urine sediment by Microscopy high power field 3 /[HPF]
Reference <=5 /[HPF]
http://loinc.org · 5821-4
S 2026-02-17 Hemoglobin [Mass/volume] in Blood 13.6 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-02-17 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-02-17 Potassium [Moles/volume] in Serum or Plasma 4.7 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-02-17 Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-02-17 Urea nitrogen [Mass/volume] in Serum or Plasma 27 mg/dL (high)
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-02-17 Creatinine [Mass/volume] in Serum or Plasma 1.42 mg/dL (high)
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-02-17 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 50 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-17 Glucose [Mass/volume] in Serum or Plasma 97 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-02-17 Prostate specific Ag [Mass/volume] in Serum or Plasma 4.9 ng/mL
Reference Age-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasteride
http://loinc.org · 2857-1
S 2026-03-03 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-03 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-03 Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-03-03 Urea nitrogen [Mass/volume] in Serum or Plasma 18 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-03-03 Creatinine [Mass/volume] in Serum or Plasma 1.18 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-03-03 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 63 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-03 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-03 Prostate Volume by derived from height, width and length (US) 85 mL (high)
Reference <=30 mL
http://loinc.org · 15308-0
S 2026-03-17 Leukocytes [#/volume] in Blood by Automated count 13.8 10*3/uL (high)
Reference 3.4-9.6 10*3/uL
http://loinc.org · 6690-2
S 2026-03-17 Hemoglobin [Mass/volume] in Blood 13.4 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2026-03-17 Sodium [Moles/volume] in Serum or Plasma 136 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-17 Potassium [Moles/volume] in Serum or Plasma 4.5 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-17 Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-03-17 Urea nitrogen [Mass/volume] in Serum or Plasma 25 mg/dL (high)
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-03-17 Creatinine [Mass/volume] in Serum or Plasma 1.31 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-03-17 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 mL/min/1.73 m² (low)
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-17 Glucose [Mass/volume] in Serum or Plasma 112 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-17 Leukocytes [#/area] in Urine sediment by Microscopy high power field 60 /[HPF] (high)
Reference <=5 /[HPF]
http://loinc.org · 5821-4
S 2026-03-31 US Urinary bladder Volume post void 420 mL (high)
Reference <=100 mL
http://loinc.org · 98856-8
S 2026-03-31 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-03-31 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-31 Carbon dioxide, total [Moles/volume] in Serum or Plasma 24 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-03-31 Urea nitrogen [Mass/volume] in Serum or Plasma 19 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-03-31 Creatinine [Mass/volume] in Serum or Plasma 1.16 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-03-31 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 64 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-31 Glucose [Mass/volume] in Serum or Plasma 95 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-03-31 Total score [Mini-Cog] 4 http://loinc.org · 72233-0
S 2026-06-09 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-07-14 US Urinary bladder Volume post void 150 mL (high)
Reference <=100 mL
http://loinc.org · 98856-8
S 2026-07-14 Symptom score [AUASI] 13 http://loinc.org · 80891-5
S 2026-07-14 If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] 3 http://loinc.org · 81090-3
S 2026-07-14 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-07-14 Potassium [Moles/volume] in Serum or Plasma 4.5 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-07-14 Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 mmol/L
Reference 22-29 mmol/L
http://loinc.org · 2028-9
S 2026-07-14 Urea nitrogen [Mass/volume] in Serum or Plasma 18 mg/dL
Reference 8-23 mg/dL
http://loinc.org · 3094-0
S 2026-07-14 Creatinine [Mass/volume] in Serum or Plasma 1.12 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-07-14 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 66 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-07-14 Glucose [Mass/volume] in Serum or Plasma 93 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-07-14 Prostate specific Ag [Mass/volume] in Serum or Plasma 2.6 ng/mL
Reference Age-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasteride
http://loinc.org · 2857-1

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-02-17Body height183 cm8302-2S
2026-02-17Body weight66 kg29463-7S
2026-02-17Body mass index (BMI) [Ratio]19.7 kg/m239156-5S
2026-02-17Systolic blood pressure138 mm[Hg]8480-6S
2026-02-17Diastolic blood pressure78 mm[Hg]8462-4S
2026-02-17Heart rate76 /min8867-4S
2026-02-17Respiratory rate16 /min9279-1S
2026-02-17Body temperature36.7 Cel8310-5S
2026-02-17Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-03-03Body height183 cm8302-2S
2026-03-03Body weight65.8 kg29463-7S
2026-03-03Body mass index (BMI) [Ratio]19.6 kg/m239156-5S
2026-03-03Systolic blood pressure132 mm[Hg]8480-6S
2026-03-03Diastolic blood pressure76 mm[Hg]8462-4S
2026-03-03Heart rate72 /min8867-4S
2026-03-03Respiratory rate16 /min9279-1S
2026-03-03Body temperature36.6 Cel8310-5S
2026-03-03Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-03-17Body height183 cm8302-2S
2026-03-17Body weight65.1 kg29463-7S
2026-03-17Body mass index (BMI) [Ratio]19.4 kg/m239156-5S
2026-03-17Systolic blood pressure118 mm[Hg]8480-6S
2026-03-17Diastolic blood pressure68 mm[Hg]8462-4S
2026-03-17Heart rate98 /min8867-4S
2026-03-17Respiratory rate18 /min9279-1S
2026-03-17Body temperature38.4 Cel8310-5S
2026-03-17Oxygen saturation in Arterial blood by Pulse oximetry96 %59408-5S
2026-03-31Body height183 cm8302-2S
2026-03-31Body weight65.3 kg29463-7S
2026-03-31Body mass index (BMI) [Ratio]19.5 kg/m239156-5S
2026-03-31Systolic blood pressure128 mm[Hg]8480-6S
2026-03-31Diastolic blood pressure72 mm[Hg]8462-4S
2026-03-31Heart rate74 /min8867-4S
2026-03-31Respiratory rate16 /min9279-1S
2026-03-31Body temperature36.6 Cel8310-5S
2026-03-31Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-04-28Body height183 cm8302-2S
2026-04-28Body weight65.6 kg29463-7S
2026-04-28Body mass index (BMI) [Ratio]19.6 kg/m239156-5S
2026-04-28Systolic blood pressure130 mm[Hg]8480-6S
2026-04-28Diastolic blood pressure74 mm[Hg]8462-4S
2026-04-28Heart rate72 /min8867-4S
2026-04-28Respiratory rate16 /min9279-1S
2026-04-28Body temperature36.6 Cel8310-5S
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-06-09Body height183 cm8302-2S
2026-06-09Body weight66 kg29463-7S
2026-06-09Body mass index (BMI) [Ratio]19.7 kg/m239156-5S
2026-06-09Systolic blood pressure132 mm[Hg]8480-6S
2026-06-09Diastolic blood pressure76 mm[Hg]8462-4S
2026-06-09Heart rate70 /min8867-4S
2026-06-09Respiratory rate16 /min9279-1S
2026-06-09Body temperature36.7 Cel8310-5S
2026-06-09Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-07-14Body height183 cm8302-2S
2026-07-14Body weight66.2 kg29463-7S
2026-07-14Body mass index (BMI) [Ratio]19.8 kg/m239156-5S
2026-07-14Systolic blood pressure130 mm[Hg]8480-6S
2026-07-14Diastolic blood pressure74 mm[Hg]8462-4S
2026-07-14Heart rate70 /min8867-4S
2026-07-14Respiratory rate16 /min9279-1S
2026-07-14Body temperature36.6 Cel8310-5S
2026-07-14Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Bladder drained and kidney function back to normal within two weeks2026-03-03completedCreatinine 1.42 mg/dL at presentation, 1.18 mg/dL after two weeks of drainage; no hydronephrosis
No catheter-associated infection, or prompt treatment if one occurs2026-03-31completedOne febrile catheter-associated infection at four weeks, treated in clinic for 7 days without admission; resolved
A treatment decision that he understands and that fits his values, after a geriatric assessment, by about ten weeks2026-04-28completedChose to continue the catheter with tamsulosin and finasteride and to try again without the catheter after three to four months, deferring surgery; recorded in his own words
Voiding without a catheter, with a post-void residual under 300 mL, by about five months2026-07-14completedSecond trial without catheter succeeded: residual 150 mL, IPSS 13
Goals of care and a health care agent recorded2026-06-09completedGoals of care discussed at the ten-week visit; health care agent named and his wishes recorded at the wellness visit

Interventions

InterventionStatusGuideline
Evaluation: IPSS with the quality-of-life question, bladder scan for post-void residual, urinalysis and urine culture, blood count, creatinine and electrolytes, digital rectal examination, and a kidney and bladder ultrasound for obstruction; a frequency-volume chart once voidingcompletedGL-AUA-BPH-2021, GL-AUA-CUR-2017, GL-CMID-2026
PSA only after shared decision-making: it helps estimate prostate size and choose treatment; screening for prostate cancer is not recommended at his age, and he would not want treatment for a slow-growing cancer; drawn before the catheter is placed, because retention and catheters raise itcompletedGL-AUA-BPH-2021, GL-USPSTF-PROSTATE-2018, GL-CMID-2026
Indwelling urethral catheter to drain the bladder, with a closed drainage system, the bag below the bladder, daily washing with soap and water, no routine antibiotics or bladder washouts, no treatment of bacteria in the urine without symptoms, a change every four weeks, and same-day review for fever, pain, blood, or a blocked cathetercompletedGL-IDSA-CAUTI-2009, GL-AUA-CUR-2017
Tamsulosin 0.4 mg at bedtime for at least three days and usually several weeks before a trial without catheter; fall precautions: take it after the evening meal, rise slowly, sit to pass urine at night, and use a night lightcompletedGL-AUA-BPH-2021, GL-BEERS-2023
Urology consultation for chronic urinary retention with a raised creatinine: confirm the cause, judge the risk, plan the trial without catheter, advise on a 5-alpha-reductase inhibitor, and set out the procedures that suit a frail 79-year-old who wants to avoid an operationcompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017
Medication review with the AGS Beers Criteria: avoid anticholinergic drugs for bladder symptoms while in retention, first-generation antihistamines, and benzodiazepines; avoid nonselective alpha-blockers; review his herbal preparation with the pharmacist for interactions and unlabeled ingredientscompletedGL-BEERS-2023, GL-AYUR-METALS-2008
Monitor on the CMID and AUA schedule: IPSS at every visit once voiding; post-void residual with each trial without catheter and after it; creatinine with retention; PSA at baseline and six months after starting finasteride, doubled for interpretation; response to tamsulosin at four to twelve weeks and to finasteride at three to six monthscompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026
Geriatric assessment before any surgical decision: frailty, gait and falls, orthostatic blood pressure on tamsulosin, cognition, mood, delirium risk, nutrition, and what matters most to himcompletedGL-BEERS-2023, GL-AUA-BPH-2021
Finasteride 5 mg daily for the 85 mL prostate, with a new PSA baseline after six months (measured value doubled for interpretation); trial without catheter after about six weeks of tamsulosin, once any infection is treatedcompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026
Surgical options counseled after the failed trial without catheter: laser enucleation (HoLEP) recommended for an 85 mL prostate with refractory retention; transurethral resection and simple prostatectomy as alternatives; prostatic artery embolization under local anesthesia as a less invasive option with less durable results; prostatic urethral lift and water vapor therapy less suitable for this size, median lobe, and retention; each weighed against his frailty, delirium risk, and wishescompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-BEERS-2023
His decision, in his own terms: defer any operation or procedure; keep the catheter, changed every four weeks, with tamsulosin and finasteride; a second trial without catheter after three to four months of finasteride; reconsider prostatic artery embolization, then laser enucleation, if that fails or if infections recur, bleeding, stones, or kidney harm develop; continue his herbal preparation after the pharmacist's reviewcompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 NobelPrize.org (Nobel Prize Outreach) biography
SRC-0002 The Nobel Prize in Literature 1913: Summary NobelPrize.org (Nobel Prize Outreach) other
SRC-0003 Rabindranath Tagore Wikipedia other
SRC-0004 History Visva-Bharati other
SRC-0005 Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 Scottish Centre of Tagore Studies (Gitanjali and Beyond) scholarly
SRC-0006 Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore Asia Times other
SRC-0007 Dinda A. India pays homage to Tagore on his 75th death anniversary Gulf News other
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the retention work-up, the PSA decision, catheter care and the infection treatment, the trials without catheter, finasteride, the surgical options for an 85 mL prostate in a frail man, the Beers review, and the recorded deviation.
provenance reviewnot_startedNobel Prize biography and citation, Wikipedia, the Visva-Bharati history page, a journal review of five memoirs by women who nursed him, and two news reports of a 2016 exhibition and a 2018 reconstruction logged. The 1937 and 1940 illnesses, his preference for traditional treatment, his fear of the operation, its date, and his death are D; the enlarged prostate, the nature of the operation, the cause of death, and prostate cancer are R and conflict. No statement, decision, or health fact is attributed to a relative, caregiver, or historical physician in the modern episode.
safe messaging reviewnot_startedHis death is recorded as a fact without detail. His reluctance about surgery and his trust in traditional medicine are recorded with respect, as documented. PHQ-2 is negative, so no safety assessment is required.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.